ReviewGynecologic oncology reports2026
Trastuzumab deruxtecan (T-DXd) in HER2-expressing gynecological malignancies: Clinical evidence, safety profile, and future directions.
Review in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial, ovarian, and cervical cancers in advanced or recurrent stages are associated with unfavorable outcomes, emphasizing the need for effective targeted approaches. While HER2 has been identified as a key biomarker in selected high-grade tumors, prior HER2-targeted therapies have yielded inconsistent results. This review discusses the underlying biology, clinical outcomes, safety considerations, and evolving application of trastuzumab deruxtecan (T-DXd) in HER2-positive gynecological cancers. T-DXd is a HER2-directed antibody-drug conjugate of a monoclonal antibody linked to a potent topoisomerase I inhibitor, allowing targeted delivery and a bystander killing effect. Evidence from trials such as DESTINY-PanTumor02 and STATICE demonstrates meaningful and sustained responses across HER2-positive gynecological malignancies, with the greatest benefit observed in IHC 3 + tumors. While the overall safety profile of T-DXd is manageable, interstitial lung disease or pneumonitis represents a key adverse event and requires timely recognition and intervention. T-DXd represents an emerging therapeutic option for HER2-positive gynecological malignancies after prior treatment, especially in advanced lines of therapy. Further studies focusing on biomarker refinement, sequencing approaches, and toxicity mitigation will be key to establishing its place in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.